NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

NOVN.CH

113.89

+0.11%↑

LONN.CH

493.4

+3.09%↑

SDZ.CH

65.52

+3.97%↑

STMN.CH

83.44

-4.2%↓

BANB.CH

74.8

+0.94%↑

Home・Akcijų sąrašas・Roche Holding AG

Roche Holding AG

Uždarymo kaina

SektoriusSveikatos priežiūra

325.6 0.74

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

325.4

Max

326.6

Pagrindiniai rodikliai
By Trading Economics
Pajamos	1.8B 5.5B
Pardavimai	15B 31B
P/E Sektoriaus vid.	20.461 67.147
Dividendų pajamingumas	2.97
Pelno marža	17.892
Darbuotojai	103,249
EBITDA	5.1B 12B

Dividendai
By Dow Jones
Dividendų pajamingumas Sektoriaus vid.	2.97% 2.36%

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-28B 261B
Ankstesnė atidarymo kaina	324.86
Ankstesnė uždarymo kaina	325.6

Naujienos nuotaikos

By Acuity

14%

86%

24 / 347 reitingas Healthcare

Roche Holding AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-23 07:46; UTC

Uždarbis

Roche Backs Full-Year View as Quarterly Sales Rise -- Update

2026-04-23 05:40; UTC

Uždarbis

Roche Backs Full-Year View as Quarterly Sales Rise

2026-03-09 16:43; UTC

Pagrindinės rinkos jėgos

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study -- Update

2026-03-09 15:44; UTC

Pagrindinės rinkos jėgos

Correction to Roche Shares Article

2026-03-09 09:51; UTC

Pagrindinės rinkos jėgos

Roche Shares Fall After Breast-Cancer Treatment Misses Goal in Late-Stage Study

2026-03-06 09:24; UTC

Pagrindinės rinkos jėgos

Zealand Pharma Shares Plunge After Obesity Drug Candidate Disappoints in Trial

2026-01-29 10:07; UTC

Uždarbis

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

2026-01-29 07:07; UTC

Uždarbis

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

2026-04-27 09:54; UTC

Rinkos pokalbiai

Roche's Vabysmo U.S. Recovery Will Be Key -- Market Talk

2026-04-23 08:10; UTC

Rinkos pokalbiai

Uždarbis

Roche Reports In Line Sales Figures -- Market Talk

2026-04-23 05:04; UTC

Uždarbis

Roche Backs 2026 View

2026-04-23 05:04; UTC

Uždarbis

Roche Diagnostics Division 1Q Sales Up at 3% Constant Currency

2026-04-23 05:03; UTC

Uždarbis

Roche Pharmaceutical Division 1Q Sales Up 7% at Constant Currency

2026-04-23 05:02; UTC

Uždarbis

Roche 1Q Group Sales Up 6% at Constant Currency

2026-04-23 05:02; UTC

Uždarbis

Analysts Saw Roche 1Q Sales at CHF14.73B

2026-04-23 05:01; UTC

Uždarbis

Roche 1Q Sales CHF14.72B

2026-04-10 11:28; UTC

Rinkos pokalbiai

Roche's Longer-Term Outlook to Take Spotlight at Diagnostics Event -- Market Talk

2026-04-10 11:17; UTC

Rinkos pokalbiai

Roche to Face Significant Currency Headwinds -- Market Talk

2026-03-11 10:57; UTC

Rinkos pokalbiai

Roche Sees Mixed Fortunes in Immunology, Oncology -- Market Talk

2026-03-09 09:43; UTC

Karštos akcijos

Stocks to Watch Monday: Lamb Weston, Carnival, Pfizer -- WSJ

2026-03-06 07:22; UTC

Rinkos pokalbiai

Roche, Zealand Pharma Obesity Drug Falls Short of Expectations -- Market Talk

2026-03-03 07:22; UTC

Rinkos pokalbiai

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2026-03-02 14:21; UTC

Rinkos pokalbiai

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

2026-01-29 11:40; UTC

Rinkos pokalbiai

Uždarbis

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

2026-01-29 06:05; UTC

Uždarbis

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

2026-01-29 06:04; UTC

Uždarbis

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

2026-01-29 06:03; UTC

Uždarbis

Roche Issues 2026 View

2026-01-29 06:02; UTC

Uždarbis

Analysts Saw 2025 Core EPS at CHF19.70

2026-01-29 06:02; UTC

Uždarbis

Roche: 2025 Core EPS CHF19.46

2026-01-29 06:01; UTC

Uždarbis

Analysts Had Seen 2025 Sales At CHF61.47B

Akcijų palyginimas

Kainos pokytis

Roche Holding AG Prognozė

Bendras įvertinimas

By TipRanks

0 ratings

Pirkti

Laikyti

Parduoti

Remiantis 0 analitikų, pateikusių Roche Holding AG akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

24 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.